iRadimed Corporation (NASDAQ:IRMD) Director Monty K. Allen sold 1,898 shares of the business’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $13.95, for a total transaction of $26,477.10. Following the transaction, the director now owns 9,062 shares in the company, valued at $126,414.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
iRadimed Corporation (NASDAQ IRMD) traded down $0.45 during trading on Friday, reaching $13.10. 12,083 shares of the company traded hands, compared to its average volume of 14,167. iRadimed Corporation has a 1-year low of $7.85 and a 1-year high of $15.00. The stock has a market capitalization of $143.02, a PE ratio of 104.23 and a beta of 1.61.
iRadimed (NASDAQ:IRMD) last released its quarterly earnings results on Monday, October 30th. The medical equipment provider reported $0.07 earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.35. iRadimed had a net margin of 6.51% and a return on equity of 4.58%. The business had revenue of $5.69 million for the quarter, compared to analysts’ expectations of $5.60 million. During the same period in the previous year, the company earned $0.14 earnings per share. The firm’s revenue for the quarter was down 25.9% compared to the same quarter last year. equities research analysts predict that iRadimed Corporation will post 0.05 EPS for the current fiscal year.
IRMD has been the topic of several analyst reports. Credit Suisse Group initiated coverage on shares of iRadimed in a report on Monday, November 27th. They set a “buy” rating and a $19.00 price target on the stock. Roth Capital initiated coverage on shares of iRadimed in a report on Tuesday, October 31st. They set a “buy” rating and a $16.00 price target on the stock. ValuEngine upgraded shares of iRadimed from a “sell” rating to a “hold” rating in a report on Friday, October 6th. Finally, Zacks Investment Research cut shares of iRadimed from a “buy” rating to a “hold” rating in a report on Monday, October 2nd. Two research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $15.33.
A number of hedge funds have recently made changes to their positions in the business. Ameriprise Financial Inc. raised its position in iRadimed by 32.9% in the third quarter. Ameriprise Financial Inc. now owns 456,810 shares of the medical equipment provider’s stock worth $4,386,000 after acquiring an additional 113,190 shares during the period. Connors Investor Services Inc. raised its position in iRadimed by 10.0% in the second quarter. Connors Investor Services Inc. now owns 33,000 shares of the medical equipment provider’s stock worth $284,000 after acquiring an additional 3,000 shares during the period. Citigroup Inc. raised its position in iRadimed by 50.8% in the second quarter. Citigroup Inc. now owns 16,082 shares of the medical equipment provider’s stock worth $138,000 after acquiring an additional 5,418 shares during the period. Menta Capital LLC raised its position in iRadimed by 5.7% in the second quarter. Menta Capital LLC now owns 70,476 shares of the medical equipment provider’s stock worth $606,000 after acquiring an additional 3,823 shares during the period. Finally, Neuberger Berman Group LLC raised its position in iRadimed by 23.3% in the second quarter. Neuberger Berman Group LLC now owns 18,500 shares of the medical equipment provider’s stock worth $159,000 after acquiring an additional 3,500 shares during the period. 13.83% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This report was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2017/12/10/monty-k-allen-sells-1898-shares-of-iradimed-corporation-irmd-stock.html.
IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.
Receive News & Ratings for iRadimed Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRadimed Corporation and related companies with MarketBeat.com's FREE daily email newsletter.